Vaxart
VXRT
VXRT was delisted on the 7th of July, 2025.
49 hedge funds and large institutions have $29.5M invested in Vaxart in 2014 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 18 reducing their positions, and 14 closing their positions.
15% less capital invested
Capital invested by funds: $34.6M → $29.5M (-$5.05M)
16% less funds holding
Funds holding: 58 → 49 (-9)
33% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 18
64% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 14
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $203K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$3.88M |
| 2 |
DMK
David M. Knott
|
+$470K |
| 3 |
SAM
Senzar Asset Management
New York
|
+$258K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$169K |
| 5 |
Renaissance Technologies
New York
|
+$74.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$2.08M |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$604K |
| 3 |
JP Morgan Chase
New York
|
-$423K |
| 4 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
-$415K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$394K |
VXRT Hedge Fund Activity: Q3 2014 in Review
49 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Vaxart (VXRT) for Q3 2014, worth a combined $29.5M — down 15% from $34.6M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of VXRT and 5 opened new positions — a net loss of 9 holders — while 18 trimmed existing stakes and 12 added.
The largest buyer was Broadfin Capital, adding an estimated $3.88M. The largest seller was DAFNA Capital Management, exiting entirely with an estimated $2.08M sold.
- 49 institutional investors held Vaxart (VXRT) as of Q3 2014, down from 58 in Q2 2014.
- Funds reported $29.5M of Vaxart stock for Q3 2014, down 15% quarter-over-quarter.
- 5 funds opened new Vaxart positions in Q3 2014 and 14 closed out, a net change of -9 holders.
- The largest Vaxart buyer in Q3 2014 was Broadfin Capital, an estimated $3.88M added.
- The largest Vaxart seller in Q3 2014 was DAFNA Capital Management, an estimated $2.08M sold.
Based on aggregated 13F filings for Q3 2014.